Prognostic and clinicopathological value of PD-L1 and HER2 in colorectal cancer

Krsteska, Blagica and Filipovski, Vanja and Kubelka-Sabit, Katerina and Jasar, Dzengis and Bogdanovska Todorovska, Magdalena and Velickova, Nevenka (2024) Prognostic and clinicopathological value of PD-L1 and HER2 in colorectal cancer. In: Second Internists Gastroenterohepatology meeting with international participation, 26-27 Apr 2024, Skopje.

	Text Krsteska, B. Prognostic and clinicopathological value of PD-L1 and HER2 in colorectal cancer.pdf Download (4MB)
	Text Abstarct book_Second Internists Gastroenterohepatology meeting with international participation.pdf Download (747kB)

Abstract

Objective: The prognostic value of PD-L1 and HER2 in colorectal cancer is current subject in many studies, systematic reviews and meta-analysis. Our aim in this study is to evaluate the expression of PD-L1 and HER2 and to analyze the relationship with clinicopathological characteristics in metastatic colorectal carcinoma (mCRC).
Materials and methods: mCRC was diagnosed in 90 cases at Clinical Hospital Acibadem – Sistina and all were stained immunohistochemically with PD-L1 using clone SP263 and HER2 clone 4B5 in tissue microarray. The expression of PD-L1 was evaluated with different cut-offs of >1%, >10%, >50% of tumor cells. The expression of HER2 was evaluated as in gastric carcinoma with scores of 1+, 2+ and 3+.
Results: Positive expression of PD-L1 was evaluated in 17cases (18,8%). Ten were male patients and 7 were females. Eighty eight percent of the positive cases were patients with age more than 50 years. More than a half of positive cases (10) showed cut off >1%. Four percent of positive cases showed cut off >10% and all of them were located in rectosigmoid colon with stage IIIB and IIIC. Three cases were evaluated with a cut off >50% all of them G3 mCRC, stage IIIC and IVA, of which 2 cases were in right colon associated with BRAF mutations. There were 36 (40%) positive cases of HER2, of which 32 were with 2+, and 4 cases expressed 3+. Ten cases of HER positive cases were located in right colon and 26 mCRC were in left colon. Twelve HER2 positive cases(33%) had KRAS/NRAS mutations, 5(13%) had BRAF mutation and 3(3%) were with MSI. 3+ positive cases showed no BRAF mutations and were MSS tumors.
Conclusion: Expression of PD-L1 was found in almost twenty percent of the cases. A higher cut off was correlated with higher grade, high pathological stage and BRAF mutation. This suggests that mCRC with high PD-L1 expression may show a survival advantage with immune checkpoint inhibitors therapy. Whilst HER2 amplified mCRC is a rare occurrence, the importance of the identification of this small group of CRCs is imperative as it represents an opportunity for effective therapeutic targeting. Targeted therapy using small molecule and antibody-based therapy might show encouraging results.

Item Type:	Conference or Workshop Item (Speech)
Subjects:	Medical and Health Sciences > Basic medicine Medical and Health Sciences > Clinical medicine
Divisions:	Faculty of Medical Science
Depositing User:	Nevenka Velickova
Date Deposited:	03 Jun 2024 08:37
Last Modified:	03 Jun 2024 08:37
URI:	https://eprints.ugd.edu.mk/id/eprint/34198

Actions (login required)

View Item